Pemigatinib is a type of inhibitor that goes afterFGFR signaling. It’s really good at fighting cholangiocarcinoma, especially when there are FGFR2 fusions involved. The drug comes in three doses: 4.5 mg, 9 mg, and 13.5 mg.
You’re supposed to take 13.5 mg every day for 14 days in a row, then take a break for 7 more days to make it a 21-day cycle. These tablets come in bottles with 14 tablets in each one.
Reviews
There are no reviews yet.